Commission Delegated Regulation (EU) 2021/849 of 11 March 2021 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)
Date: 2021-03-11
Institutions: Directorate-General for Environment, European Commission
Subjects: classification, dangerous substance, environmental protection, labelling, packaging, public health, technological change








L_2021188EN.01002701.xml










28.5.2021   


EN


Official Journal of the European Union


L 188/27








            COMMISSION DELEGATED REGULATION (EU) 2021/849
of 11 March 2021
         
amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures
(Text with EEA relevance)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:







(1)


Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.












(2)


Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted opinions (2) on those proposals, after having taken account of the comments received from the parties concerned. Those RAC opinions are:






—


Opinion of 15 March 2019 concerning 1,2,4-triazole,










—


Opinion of 15 March 2019 concerning 1,4-dioxane,










—


Opinion of 15 March 2019 concerning benzyl salicylate,










—


Opinion of 15 March 2019 concerning flumioxazin (ISO),










—


Opinion of 15 March 2019 concerning mancozeb (ISO),










—


Opinion of 15 March 2019 concerning M-factors for long-term aquatic hazard for the copper substances listed in Commission Regulation (EU) 2016/1179,










—


Opinion of 15 March 2019 concerning N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane,










—


Opinion of 15 March 2019 concerning N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen,










—


Opinion of 15 March 2019 concerning p-cymene; 1-isopropyl-4-methylbenzene,










—


Opinion of 15 March 2019 concerning p-mentha-1,3-diene; alpha-terpinene; 1-isopropyl-4-methylcyclohexa-1,3-diene,










—


Opinion of 15 March 2019 concerning prothioconazole,










—


Opinion of 15 March 2019 concerning (R)-p-mentha-1,8-diene; d-limonene,










—


Opinion of 15 March 2019 concerning thiophanate-methyl,










—


Opinion of 15 March 2019 concerning tolclofos-methyl (ISO); O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate,










—


Opinion of 15 March 2019 concerning tolpyralate,










—


Opinion of 15 March 2019 concerning trinickel disulphide,










—


Opinion of 13 June 2019 concerning azamethiphos,










—


Opinion of 13 June 2019 concerning 2-phenoxyethanol,










—


Opinion of 13 June 2019 concerning 2,2-dibromo-2-cyanoacetamide,










—


Opinion of 13 June 2019 concerning 3-aminomethyl-3,5,5-trimethylcyclohexylamine,










—


Opinion of 13 June 2019 concerning 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol,










—


Opinion of 13 June 2019 concerning diflufenican (ISO) N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide,










—


Opinion of 13 June 2019 concerning imidacloprid (ISO); 1-(6-chloropyridin-3-ylmethyl)-N-nitroimidazolidin-2-ylidenamine,










—


Opinion of 13 June 2019 concerning pyriofenone,










—


Opinion of 13 June 2019 concerning S-abscisic acid,










—


Opinion of 13 June 2019 concerning tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate,










—


Opinion of 20 September 2019 concerning 1,2-epoxy-4-epoxyethylcyclohexane,










—


Opinion of 20 September 2019 concerning 4-methylpentan-2-one,










—


Opinion of 20 September 2019 concerning boric acid; diboron trioxide; tetraboron disodium heptaoxide hydrate; disodium tetraborate anhydrous; orthoboric acid sodium salt; disodium tetraborate decahydrate; disodium tetraborate pentahydrate,










—


Opinion of 20 September 2019 concerning citric acid,










—


Opinion of 20 September 2019 concerning clomazone,










—


Opinion of 20 September 2019 concerning desmedipham,










—


Opinion of 20 September 2019 concerning dimethomorph,










—


Opinion of 20 September 2019 concerning emamectin benzoate,










—


Opinion of 20 September 2019 concerning esfenvalerate (ISO) (S)-α-cyano-3-phenoxybenzyl (S)-2-(4-chlorophenyl)-3-methylbutyrate,










—


Opinion of 20 September 2019 concerning ethametsulfuron-methyl (ISO),










—


Opinion of 20 September 2019 concerning mecoprop-P (ISO); (R)-2-(4-chloro-2-methylphenoxy)propionic acid and its salts,










—


Opinion of 20 September 2019 concerning methyl salicylate,










—


Opinion of 20 September 2019 concerning phenmedipham (ISO),










—


Opinion of 20 September 2019 concerning trifloxystrobin (ISO),










—


Opinion of 20 September 2019 concerning triticonazole,










—


Opinion of 5 December 2019 concerning 1,4-dimethylnaphthalene,










—


Opinion of 5 December 2019 concerning (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide,










—


Opinion of 5 December 2019 concerning 3-methylpyrazole,










—


Opinion of 5 December 2019 concerning carbendazim (ISO); methyl benzimidazol-2-ylcarbamate,










—


Opinion of 5 December 2019 concerning cypermethrin cis/trans +/- 40/60; (RS)-α-cyano-3-phenoxybenzyl (1RS,3RS;1RS,3SR)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate,










—


Opinion of 5 December 2019 concerning imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid,










—


Opinion of 5 December 2019 concerning tetrafluoroethylene,










—


Opinion of 5 December 2019 concerning thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine,










—


Opinion of 5 December 2019 concerning trinexapac-ethyl (ISO); ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate.
















(3)


Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessmentsof some substances, ATE values have been derived by the Agency for dicopper oxide, dicopper chloride trihydroxide, tetracopper hexahydroxide sulphate and tetracopper hexahydroxide sulphate hydrate, copper flakes (coated with aliphatic acid), copper(II) carbonate--copper(II) hydroxide (1:1), copper dihydroxide; copper(II) hydroxide, bordeaux mixture; reaction products of copper sulphate with calcium dihydroxide and copper sulphate pentahydrate, in addition to those proposed in the RAC opinions for other substances. Those ATE values should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008.












(4)


Additional information was received by the Commission contesting the scientific assessment set out in the RAC opinions of 15 March 2019 concerning mancozeb, of 20 September 2019 concerning 4-methylpentan-2-one, and of 20 September 2019 concerning dimethomorph. That information was assessed by the Commission and was not found sufficient to cast doubts on the scientific analysis contained in the RAC opinions.












(5)


The Commission therefore considers appropriate to introduce, update or delete the harmonised classification and labelling of certain substances.












(6)


Regulation (EC) No 1272/2008 should therefore be amended accordingly.












(7)


Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or revised classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Such requirements may include those set out in point (f) of Article 22(1) of Regulation (EC) No 1907/2006 of the European Parliament and of the Council (3) or those set out in Article 50 of Regulation (EU) No 528/2012 of the European Parliament and of the Council (4). Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation and as of the date of entry into force to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,





HAS ADOPTED THIS REGULATION:



Article 1

Amendments to Regulation (EC) No 1272/2008

Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.


Article 2

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 17 December 2022.
By way of derogation from the second paragraph of this Article, substances and mixtures may be classified, labelled and packaged in accordance with this Regulation from its date of entry into force.




This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 11 March 2021.


For the Commission


The President

Ursula VON DER LEYEN
            





(1)  
            OJ L 353, 31.12.2008, p. 1.

(2)  The opinions are accessible via the following website:https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/

(3)  Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).

(4)  Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1).




ANNEX
In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:






(1)


the following entries are inserted:
















Index No




Chemical Name




EC No




CAS No




Classification




Labelling




Specific Conc. Limits, M-
factors and ATE




Notes






Hazard Class and Category Code(s)




Hazard statement Code(s)




Pictogram, Signal Word Code(s)




Hazard statement Code(s)




Suppl. Hazard statement Code(s)





‘601-093-00-6


1,4-dimethylnaphthalene


209-335-9


571-58-4


Acute Tox. 4
Asp. Tox. 1
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 3


H302
H304
H319
H400
H412


GHS07
GHS08
GHS09
Dgr


H302
H304
H319
H410


 


oral: ATE = 1 300  mg/kg bw
M = 1’


 




‘601-094-00-1


1-isopropyl-4-methylbenzene;

p-cymene


202-796-7


99-87-6


Flam. Liq. 3
Acute Tox. 3
Asp. Tox. 1
Aquatic Chronic 2


H226
H331
H304
H411


GHS02
GHS06
GHS08
GHS09
Dgr


H226
H331
H304
H411


 


inhalation: ATE = 3 mg/l (vapours)’


 




‘601-095-00-7



p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene;
alpha-terpinene


202-795-1


99-86-5


Flam. Liq. 3
Acute Tox. 4
Skin Sens. 1
Asp. Tox. 1
Aquatic Chronic 2


H226
H302
H317
H304
H411


GHS02
GHS07
GHS08
GHS09
Dgr


H226
H302
H317
H304
H411


 


oral: ATE = 1 680  mg/kg bw’


 




‘602-110-00-X


tetrafluoroethylene


204-126-9


116-14-3


Carc. 1B


H350


GHS08
Dgr


H350’


 


 


 




‘604-095-00-5


6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol;
[DBMC]


204-327-1


119-47-1


Repr. 1B


H360F


GHS08
Dgr


H360F’


 


 


 




‘606-152-00-X


(5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone


-


688046-61-9


Carc. 2
Aquatic Chronic 1


H351
H410


GHS08
GHS09
Wng


H351
H410


 


M = 1’


 




‘607-747-00-7


2,2-dibromo-2-cyanoacetamide; [DBNPA]


233-539-7


10222-01-2


Acute Tox. 2
Acute Tox. 3
STOT RE 1
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H330
H301
H372 (respiratory tract) (inhalation)
H315
H318
H317
H400
H410


GHS06
GHS08
GHS05
GHS09
Dgr


H330
H301
H372 (respiratory tract) (inhalation)
H315
H318
H317
H410


 


inhalation: ATE = 0,24 mg/l (dusts or mists)
oral: ATE = 118 mg/kg bw
M = 1
M = 1’


 




‘607-748-00-2


[S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid;

S-abscisic acid


244-319-5


21293-29-8


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 1
M = 1’


 




‘607-749-00-8


methyl salicylate


204-317-7


119-36-8


Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Chronic 3


H361d
H302
H317
H412


GHS07
GHS08
Wng


H361d
H302
H317
H412


 


oral: ATE = 890 mg/kg bw’


 




‘607-750-00-3


citric acid


201-069-1


77-92-9


Eye Irrit. 2
STOT SE 3


H319
H335


GHS07
Wng


H319
H335’


 


 


 




‘607-751-00-9


ethametsulfuron-methyl (ISO);
methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate


-


97780-06-8


Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1


H319
H400
H410


GHS07
GHS09
Wng


H319
H410


 


M = 1 000 
M = 100’


 




‘607-752-00-4


trinexapac-ethyl (ISO);
ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate


-


95266-40-3


STOT RE 2
Skin Sens. 1B
Aquatic Chronic 1


H373 (gastrointestinal tract)
H317
H410


GHS08
GHS07
GHS09
Wng


H373 (gastrointestinal tract)
H317
H410


 


M = 1’


 




‘607-753-00-X


(3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide


-


78821-43-9


Aquatic Chronic 4


H413


 


H413’


 


 


 




‘607-754-00-5


benzyl salicylate


204-262-9


118-58-1


Skin Sens. 1B


H317


GHS07
Wng


H317’


 


 


 




‘607-755-00-0


(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;
tolpyralate


-


1101132-67-5


Carc. 2
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H351
H361fd
H373 (eye)
H400
H410


GHS08
GHS09
Wng


H351
H361fd
H373 (eye)
H410


 


M = 10
M = 100’


 




‘613-337-00-9


prothioconazole (ISO);
2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione


-


178928-70-6


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 10
M = 1’


 




‘613-338-00-4


azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate


252-626-0


35575-96-3


Carc. 2
Acute Tox. 3
Acute Tox. 4
STOT SE 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H351
H331
H302
H370 (nervous system)
H317
H400
H410


GHS06
GHS08
GHS09
Dgr


H351
H331
H302
H370 (nervous system)
H317
H410


 


inhalation: ATE = 0,5 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 1 000 
M = 1 000 ’


 




‘613-339-00-X


3-methylpyrazole


215-925-7


1453-58-3


Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Corr. 1
Eye Dam. 1


H360D
H302
H373 (lung)
H314
H318


GHS08
GHS07
GHS05
Dgr


H360D
H302
H373 (lung)
H314


 


oral: ATE = 500 mg/kg bw’


 




‘613-340-00-5


clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one


-


81777-89-1


Acute Tox. 4
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1


H332
H302
H400
H410


GHS07
GHS09
Wng


H332
H302
H410


 


inhalation: ATE = 4,85 mg/l (dusts or mists)
oral: ATE = 768 mg/kg bw
M = 1
M = 1’


 




‘614-030-00-2


emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate


-


155569-91-8


Acute Tox. 3
Acute Tox. 3
Acute Tox. 3
STOT SE 1
STOT RE 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H331
H311
H301
H370 (nervous system)
H372 (nervous system)
H318
H400
H410


GHS06
GHS05
GHS08
GHS09
Dgr


H331
H311
H301
H370 (nervous system)
H372 (nervous system)
H318
H410


 


inhalation:
ATE = 0,663
mg/l (dusts or mists)
dermal:
ATE = 300
mg/kg bw
oral: ATE =
60 mg/kg bw
STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 %
M = 10 000 
M = 10 000 ’


 




‘616-234-00-7



N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen


-


1228284-64-7


Carc. 2
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1


H351
H361f
H400
H410


GHS08
GHS09
Wng


H351
H361f
H410


 


M = 1
M = 1’


 




‘616-235-00-2



N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane


-


874967-67-6


Carc. 2
Aquatic Acute 1
Aquatic Chronic 2


H351
H400
H411


GHS08
GHS09
Wng


H351
H410


 


M = 1’


 














(2)


the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively:
















Index No




Chemical Name




EC No




CAS No




Classification




Labelling




Specific Conc. Limits, M- factors and ATE




Notes






Hazard Class and Category Code(s)




Hazard statement Code(s)




Pictogram, Signal Word Code(s)




Hazard statement Code(s)




Suppl. Hazard statement Code(s)





‘005-007-00-2


boric acid [1]
boric acid [2]


233-139-2 [1]
234-343-4 [2]


10043-35-3 [1]
11113-50-1 [2]


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




‘005-008-00-8


diboron trioxide


215-125-8


1303-86-2


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




‘005-011-00-4


tetraboron disodium heptaoxide, hydrate; [1]
disodium tetraborate, anhydrous; [2]
orthoboric acid, sodium salt [3]
disodium tetraborate decahydrate [4]
disodium tetraborate pentahydrate [5]


235-541-3 [1]
215-540-4 [2]
237-560-2 [3]
215-540-4 [4]
215-540-4 [5]


12267-73-1 [1]
1330-43-4 [2]
13840-56-7 [3]
1303-96-4 [4]
12179-04-3 [5]


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




 


 


 


 


 


 


 


 


 


 


 




 


 


 


 


 


 


 


 


 


 


 




‘006-069-00-3


thiophanate-methyl (ISO);
dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;
dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate)


245-740-7


23564-05-8


Carc. 2
Muta. 2
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H351
H341
H332
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H341
H332
H317
H410


 


inhalation: ATE = 1,7 mg/l
(dusts and mists)
M = 10
M = 10’


 




‘006-076-00-1


mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt


-


8018-01-7


Carc. 2
Repr. 1B
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H351
H360D
H373 (thyroid, nervous system)
H317
H400
H410


GHS08
GHS07
GHS09
Dgr


H351
H360D
H373 (thyroid, nervous system)
H317
H410


 


M = 10
M = 10’


 




‘015-113-00-0


tolclofos-methyl (ISO);

O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate


260-515-3


57018-04-9


Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1


H317
H400
H410


GHS07
GHS09
Wng


H317
H410


 


M = 1
M = 1’


 




‘028-007-00-4


trinickel disulfide;
nickel subsulfide; [1]
heazlewoodite [2]


234-829-6 [1]
- [2]


12035-72-2 [1]
12035-71-1 [2]


Carc. 1A
Muta. 2
Acute Tox. 3
STOT RE 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H350i
H341
H331
H372**
H317
H400
H410


GHS08
GHS06
GHS09
Dgr


H350i
H341
H331
H372**
H317
H410


 


inhalation:
ATE = 0,92 mg/l
(dusts or mists)’


 




‘029-002-00-X


dicopper oxide;
copper (I) oxide


215-270-7


1317-39-1


Acute Tox. 4
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H332
H302
H318
H400
H410


GHS07
GHS05
GHS09
Dgr


H332
H302
H318
H410


 


inhalation: ATE = 3,34 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 100
M = 10’


 




‘029-015-00-0


copper thiocyanate


214-183-1


1111-67-7


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


EUH032


M = 10
M = 10’


 




‘029-016-00-6


copper(II) oxide


215-269-1


1317-38-0


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 100
M = 10’


 




‘029-017-00-1


dicopper chloride trihydroxide


215-572-9


1332-65-6


Acute Tox. 4
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1


H332
H301
H400
H410


GHS06
GHS09
Dgr


H332
H301
H410


 


inhalation: ATE = 2,83 mg/l (dusts or mists)
oral: ATE = 299 mg/kg bw
M = 10
M = 10’


 




‘029-018-00-7


tetracopper hexahydroxide sulphate; [1]
tetracopper hexahydroxide sulphate hydrate [2]


215-582-3 [1]
215-582-3 [2]


1333-22-8 [1]
12527-76-3 [2]


Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1


H302
H400
H410


GHS07
GHS09
Wng


H302
H410


 


oral: ATE = 500 mg/kg bw
M = 10
M = 10’


 




‘029-019-01-X


copper flakes (coated with aliphatic acid)


-


-


Acute Tox. 3
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1


H331
H302
H319
H400
H410


GHS06
GHS09
Dgr


H331
H302
H319
H410


 


inhalation: ATE = 0,733 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’


 




‘029-020-00-8


copper(II) carbonate—copper(II) hydroxide (1:1)


235-113-6


12069-69-1


Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1


H332
H302
H319
H400
H410


GHS07
GHS09
Wng


H332
H302
H319
H410


 


inhalation: ATE = 1,2 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’


 




‘029-021-00-3


copper dihydroxide;
copper(II) hydroxide


243-815-9


20427-59-2


Acute Tox. 2
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H330
H302
H318
H400
H410


GHS06
GHS05
GHS09
Dgr


H330
H302
H318
H410


 


inhalation: ATE = 0,47 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’


 




‘029-022-00-9


bordeaux mixture;
reaction products of copper sulphate with calcium dihydroxide


-


8011-63-0


Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H332
H318
H400
H410


GHS07
GHS05
GHS09
Dgr


H332
H318
H410


 


inhalation: ATE = 1,97 mg/l (dusts or mists)
M = 10
M = 1’


 




‘029-023-00-4


copper sulphate pentahydrate


231-847-6


7758-99-8


Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H302
H318
H400
H410


GHS07
GHS05
GHS09
Dgr


H302
H318
H410


 


oral: ATE = 481 mg/kg bw
M = 10
M = 1’


 




‘601-029-00-7


dipentene;
limonene [1]
(S)-p-mentha-1,8-diene; l-limonene [2]

trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3]
(±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]


205-341-0 [1]
227-815-6 [2]
229-977-3 [3]
231-732-0 [4]


138-86-3 [1]
5989-54-8 [2]
6876-12-6 [3]
7705-14-8 [4]


Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H226
H315
H317
H400
H410


GHS02
GHS07
GHS09
Wng


H226
H315
H317
H410


 


 


C’




‘601-096-00-2


(R)-p-mentha-1,8-diene;
d-limonene


227-813-5


5989-27-5


Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1B
Asp. Tox. 1
Aquatic Acute 1
Aquatic Chronic 3


H226
H315
H317
H304
H400
H412


GHS02
GHS07
GHS08
GHS09
Dgr


H226
H315
H317
H304
H410


 


M = 1’


 




‘603-024-00-5


1,4-dioxane


204-661-8


123-91-1


Flam. Liq. 2
Carc. 1B
STOT SE 3
Eye Irrit. 2


H225
H350
H335
H319


GHS02
GHS08
GHS07
Dgr


H225
H350
H335
H319


EUH019
EUH066


 


D’




‘603-066-00-4


7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide


203-437-7


106-87-6


Carc. 1B
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4


H350
H341
H360F
H331
H302


GHS08
GHS06
Dgr


H350
H341
H360F
H331
H302


 


inhalation: ATE = 0,5 mg/l (dusts or mists)
oral: ATE = 1 847  mg/kg bw’


 




‘603-098-00-9


2-phenoxyethanol


204-589-7


122-99-6


Acute Tox. 4
STOT SE 3
Eye Dam. 1


H302
H335
H318


GHS05
GHS07
Dgr


H302
H335
H318


 


oral:
ATE = 1 394  mg/kg bw’


 




‘606-004-00-4


4-methylpentan-2-one; isobutyl methyl ketone


203-550-1


108-10-1


Flam. Liq. 2
Carc. 2
Acute Tox. 4
STOT SE 3
Eye Irrit. 2


H225
H351
H332
H336
H319


GHS02
GHS07
GHS08
Dgr


H225
H351
H332
H336
H319


EUH066


inhalation: ATE = 11 mg/l (vapours)’


 




‘607-421-00-4


cypermethrin (ISO);
α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60


257-842-9


52315-07-8


Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H332
H302
H335
H373 (nervous system)
H400
H410


GHS07
GHS08
GHS09
Wng


H332
H302
H335
H373 (nervous system)
H410


 


oral; ATE = 500 mg/kg bw
inhalation; ATE = 3,3 mg/l (dusts or mists)
M = 100000
M = 100000’


 




‘607-424-00-0


trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate


-


141517-21-7


Lact.
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H362
H317
H400
H410


GHS07
GHS09
Wng


H362
H317
H410


 


M = 100
M = 10’


 




‘607-434-00-5


mecoprop-P (ISO) [1] and its salts;
(R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts


240-539-0 [1]


16484-77-8 [1]


Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1


H302
H318
H400
H410


GHS07
GHS05
GHS09
Dgr


H302
H318
H410


 


oral: ATE = 431 mg/kg bw
M = 10
M = 10’


 




‘608-058-00-4


esfenvalerate (ISO);
(S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate


-


66230-04-4


Acute Tox. 3
Acute Tox. 3
STOT SE 1
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H331
H301
H370 (nervous system)
H373
H317
H400
H410


GHS06
GHS08
GHS09
Dgr


H331
H301
H370 (nervous system)
H373
H317
H410


 


oral; ATE = 88,5 mg/kg bw
inhalation; ATE = 0,53 mg/l (dusts or mists)
M = 10 000 
M = 10 000 ’


 




‘612-067-00-9


3-aminomethyl-3,5,5-trimethylcyclohexylamine


220-666-8


2855-13-2


Acute Tox. 4
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A


H302
H314
H318
H317


GHS05
GHS07
Dgr


H302
H314
H317


 


oral: ATE = 1 030  mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,001 %’


 




‘612-252-00-4


imidacloprid (ISO);
(E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine;
(2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine


428-040-8


138261-41-3


Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1


H301
H400
H410


GHS06
GHS09
Dgr


H301
H410


 


oral: ATE = 131 mg/kg bw
M = 100
M = 1 000 ’


 




‘613-048-00-8


carbendazim (ISO); methyl benzimidazol-2-ylcarbamate


234-232-0


10605-21-7


Muta. 1B
Repr. 1B
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H340
H360FD
H317
H400
H410


GHS07
GHS08
GHS09
Dgr


H340
H360FD
H317
H410


 


M = 10
M = 10’


 




‘613-102-00-0


dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine


404-200-2


110488-70-5


Repr. 1B
Aquatic Chronic 2


H360F
H411


GHS08
GHS09
Dgr


H360F
H411’


 


 


 




‘613-111-00-X


1,2,4-triazole


206-022-9


288-88-0


Repr. 1B
Acute Tox. 4
Eye Irrit. 2


H360FD
H302
H319


GHS08
GHS07
Dgr


H360FD
H302
H319


 


oral: ATE = 1 320  mg/kg bw’


 




‘613-166-00-X


flumioxazin (ISO);

N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide


-


103361-09-7


Repr. 2
Aquatic Acute 1
Aquatic Chronic 1


H361d
H400
H410


GHS08
GHS09
Wng


H361d
H410


 


M = 1 000 
M = 1 000 ’


 




‘613-208-00-7


imazamox (ISO);
(RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid


-


114311-32-9


Repr. 2
Aquatic Acute 1
Aquatic Chronic 1


H361d
H400
H410


GHS08
GHS09
Wng


H361d
H410


 


M = 10
M = 10’


 




‘613-267-00-9


thiamethoxam (ISO);
3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine


428-650-4


153719-23-4


Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1


H361fd
H302
H400
H410


GHS07
GHS08
GHS09
Wng


H361fd
H302
H410


 


oral: ATE = 780 mg/kg bw
M = 10
M = 10’


 




‘613-282-00-0


triticonazole (ISO);
(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol


-


138182-18-0


Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1


H361f
H373
H400
H410


GHS08
GHS09
Wng


H361f
H373
H410


 


M = 1
M = 1’


 




‘616-032-00-9


diflufenican (ISO);

N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide


-


83164-33-4


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 10 000 
M = 1 000 ’


 




‘616-106-00-0


phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate


237-199-0


13684-63-4


Aquatic Acute 1
Aquatic Chronic 1


H400
H410


GHS09
Wng


H410


 


M = 10
M = 10’


 




‘616-113-00-9


desmedipham (ISO);
ethyl 3-phenylcarbamoyloxyphenylcarbamate


237-198-5


13684-56-5


Repr. 2
Aquatic Acute 1
Aquatic Chronic 1


H361d
H400
H410


GHS08
GHS09
Wng


H361d
H410


 


M = 10
M = 10’


 














(3)


the entry corresponding to index number 015-192-00-1 is deleted.